Bioavailability, Metabolism, and Excretion of [14C]‐Tazemetostat in Patients With B‐Cell Lymphomas or Advanced Solid Tumors

Documenti analoghi

• Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
  di: Yingxue Chen, et al.
  Pubblicazione: (2025)
• Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [ 14 C]Xevinapant, a Potent, Oral, Small‐Molecule IAP Inhibitor
  di: Annick Menetrey, et al.
  Pubblicazione: (2026)
• Absorption, Metabolism, and Excretion of [14C]‐Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects
  di: Lijun Xie, et al.
  Pubblicazione: (2024)
• Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist
  di: Akihito Ogasawara, et al.
  Pubblicazione: (2024)
• Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations
  di: Wei Zhu, et al.
  Pubblicazione: (2024)